# BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

> **NCT02650804** · PHASE2 · COMPLETED · sponsor: **BPGbio** · enrollment: 45 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** BPM31510 Nanosuspension Injection
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02650804
- **Lead sponsor:** BPGbio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-06
- **Primary completion:** 2019-06-11
- **Final completion:** 2019-06-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650804, "BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02650804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*